A single dose bioavailability study of 2 new formulations of HKI-272 (240 mg) [neratinib] compared with a reference capsule and an oral solution in healthy adult subjects.
Phase of Trial: Phase I
Latest Information Update: 11 May 2012
At a glance
- Drugs Neratinib (Primary)
- Indications Breast cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Wyeth
- 11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 12 Dec 2007 Status change from in progress to completed.
- 11 Sep 2007 Status changed from initiated to in progress.